Lung perfusion device studied in US | Hospitals readying to help pregnant women, infants with Zika | Study: HIV-positive patients less likely to receive cancer treatment
May 18, 2016
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Lung perfusion device studied in US
The XPS device developed by Sweden's XVIVO Perfusion is being studied for the conditioning of donor lungs in clinical trials at 16 US medical centers. The device ventilates the lungs and infuses them with steroids while outside the body. Researchers are exploring whether the device can expand the pool of donor lungs.
Reuters (5/17) 
LinkedIn Twitter Facebook Google+ Email
Immucor is Your Partner in Continuing Education
Immucor is committed to supporting your laboratory's compliance requirements with complete line of competency testing kits. Gamma® Tech-Chek, Self-check II, and RiSE offer unique test cases and samples that range in complexity for varying levels of blood bank experience. Earn valuable CEU or PACE credits! Learn more.
Science & Health
Hospitals readying to help pregnant women, infants with Zika
Aedes aegypti mosquito
An Aedes aegypti mosquito, which can transmit the Zika, chikungunya, dengue and yellow fever viruses. (Luis Robayo/AFP/Getty Images)
US hospitals are bolstering care for pregnant women and infants infected with the Zika virus, amid the rising number of infections. Children's National Health System in Washington, D.C., announced its Congenital Zika Virus Program, which will treat infants, take referrals from around the nation and provide information for women with Zika, while Baylor College of Medicine and Texas Children's Hospital, both in Houston, have begun a specialized program.
USA Today (5/16) 
LinkedIn Twitter Facebook Google+ Email
Study: HIV-positive patients less likely to receive cancer treatment
Researchers reviewed data on 10,000 HIV patients who developed cancer and found they were less likely to receive treatment than a comparison group of 2.2 million HIV-negative patients with cancer. "For most cancers, HIV-infected patients were two to three times more likely to receive no cancer treatment compared to uninfected people," study author Dr. Gita Suneja said. The study was published in the journal Cancer.
HealthDay News (5/17) 
LinkedIn Twitter Facebook Google+ Email
Emerging Trends
Fresenius launches CLiC monitoring device for hemodialysis
Fresenius Renal Therapies has introduced the noninvasive CLiC device for tracking oxygen saturation, hematocrit levels and changes in intravascular blood volume during fluid removal for hemodialysis.
Nephrology News & Issues (5/16) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
Luminex signs deal to buy Nanosphere
Luminex agreed to pay $58 million plus $25 million in debt to acquire Nanosphere, an Illinois-based firm that produces molecular diagnostic assays for respiratory, gastroenteric and bloodstream infections. The transaction, which could close in the second quarter, will complement and boost Luminex's diagnostic portfolio, the company said.
American City Business Journals/Austin, Texas (5/16) 
LinkedIn Twitter Facebook Google+ Email
Novartis to divide into 2 business units
Novartis announced it will split its pharmaceuticals unit into separate drug and oncology businesses. Novartis' restructuring plan reflects its focus on oncology after consolidating GlaxoSmithKline's oncology products into its pipeline in 2015, the company said.
Reuters (5/17) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
Senate moves on $1.1B in Zika funding; House looks at $622M reallocation
The Senate voted 68 to 29 on Tuesday in favor of $1.1 billion in emergency funding to fight the Zika virus. The White House has requested $1.9 billion, while House Republicans have proposed moving $622 million from other initiatives.
The New York Times (free-article access for SmartBrief readers) (5/17) 
LinkedIn Twitter Facebook Google+ Email
Cellular Therapy: Principles, Methods, and Regulations, 2nd edition
This highly awaited release is a collection of advanced practices and methods for developing and producing cell therapy products. New in this edition are pre-clinical testing and early-phase trial development as well as international regulation of cell therapy products. Buy Now.
Association News
New releases and old favorites available as digital publications
AABB is pleased to announce that its digital publications can now be accessed from multiple devices and browsers. Highlighting, annotations and offline use are among the new features that will enable users to customize their publications for use as personal resources. Bundled discounts are available for users who need both print and digital versions of a publication. The Digital Publication Web Viewer User Guide and Frequently Asked Questions are available in the Marketplace.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Medical Technologist or Medical Laboratory Technician, FT or PT
Clinical Laboratory Scientists
The man who moves a mountain begins by carrying away small stones.
philosopher and teacher
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information